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Part I: Screen Design 
A. Characterization of Expression Profiles in Primary Cells 
Isolation of Cells and RNA 
Normal peripheral blood monocytes and neutrophils were isolated using Ficoll-Paque 
(Amersham Pharmacia Biotech) separation from three different donor leukopack samples 
provided by the Dana Farber Cancer Institute Blood Bank. The isolation of monocytes was 
confirmed with FACS analysis for CD14. We confirmed the isolation of neutrophils and 
monocytes with morphological analysis after May-Grunwald-Giemsa staining (Sigma). RNA was 
obtained using Trizol (GIBCO/BRL) as per the manufacturer’s guidelines. Quality was assessed 
by the presence of undegraded 18S and 28S ribosomal RNA bands by denaturing gel 
electrophoresis. 
Adult AML samples were obtained from the Cancer and Leukemia Group (CALGB) leukemia 
bank and processed as previously reported
1.  Samples were selected without regard to 
immunophenotype, cytogenetics, or other molecular features. After informed consent was 
obtained, mononuclear cells were isolated by Ficoll sedimentation and RNA was obtained from 
three primary patient AML cell samples as described above. 
Target Preparation and Hybridization to Microarrays 
RNA from the three patient AML samples, three normal peripheral blood monocytes and 3 
neutrophil samples (10 µg per sample) was used to create target for hybridization to DNA 
microarrays.  First strand cDNA synthesis was generated using a T7-linked oligo-dT primer, 
followed by second strand synthesis.  An in vitro transcription reaction was performed to 
generate cRNA containing biotinylated UTP and CTP, which was subsequently chemically   5
fragmented at 95° C for 35 minutes.   Ten micrograms of the fragmented, biotinylated cRNA 
was hybridized in MES buffer (2-[N-Morpholino]ethansulfonic acid) containing 0.5 mg/ml 
acetylated bovine serum albumin (Sigma, St. Louis) to Affymetrix (Santa Clara, CA) HuFL 
arrays at 45°C for 16 hours.   HuFL arrays contain 5920 known genes and 897 expressed 
sequence tags.  Arrays were washed and stained with streptavidin-phycoerythrin (SAPE, 
Molecular Probes).  Signal amplification was performed using a biotinylated anti-streptavidin 
antibody (Vector Laboratories, Burlingame, CA) at 3 µg/ml.  This was followed by a second 
staining with SAPE.  Normal goat IgG (2 mg/ml) was used as a blocking agent.  Scans were 
performed on Affymetrix scanners and average differences (expression values) were calculated 
using GeneChip MAS4 Software (Affymetrix). Minor differences in microarray intensity were 
corrected using a scaling method as detailed in the next section. 
Microarray Data Analysis 
Criteria for scan rejection included fewer than 1000 genes receiving “Present” calls or visible 
microarray artifacts.  No scans met criteria for exclusion.  The raw expression data as obtained 
from Affymetrix’s GeneChip were scaled to account for differences in chip intensities.  We 
calculated the mean expression level (E) for all genes on each array.  All scans within an 
experiment were scaled to the array with the median E value (all expression values are 
multiplied by Emedian/E). These scaled data are contained in Res File 1, 
Myeloid_primarycells.res. 
Next, we preprocessed the data by applying thresholds and filtering.  A ceiling of 16,000 units 
was chosen because we observed fluorescence saturation of the scanner at this level. A floor 
was set at 100 to minimize noise and remove negative values.  After this preprocessing, gene 
expression values were subjected to a variation filter that excluded genes showing minimal 
variation across the samples being analyzed. We limited our analysis to genes that   6
demonstrated at least a 5-fold change in relative expression level across the dataset and an 
absolute change of at least 400 units.   
For marker gene selection, we used the signal-to-noise (SNR) statistic to rank the genes that 
correlated with the AML vs. neutrophil and the AML vs. monocyte distinction 
1,2. SNR= (µo – 
µ1)/(σo + σ1) where µ and σ represent the mean and the standard deviation of the expression, 
respectively, for each class. We next needed to identify statistically significant marker genes. 
Permutation of the sample labels was performed to compare these correlations to what would 
be expected by chance as described below.  
The permutation test procedure for a given comparison of interest (e.g. markers high in class 0 
and low in class 1) is as follows: 
•  Generate signal-to-noise scores for all genes that pass a variation filter using the actual 
class labels (phenotype) and sort them accordingly.  The best match (k=1) is the gene 
“closer” or more correlated to the phenotype using the signal-to-noise as a correlation 
function. In fact, one can imagine the reciprocal of the signal-to-noise as a “distance” 
between the “phenotype” and each gene as shown in the Supplementary Fig. 1 top 
diagrams. One can also use a t-statistic (µ0 - µ1)/√(σ
2
0 + σ
2
1) and obtain very similar results. 
•  Generate 2500 random permutations of the class labels (phenotype). For each case of 
randomized class labels generate signal-to-noise scores and sort genes accordingly. 
•  Build a histogram of signal-to-noise scores for each value of k. For example, build one for 
the 500 top markers (k=1), another one for the 500 second best (k=2), etc. These 
histograms represent a reference statistic for the best match, second best, etc. where many 
genes contribute to a given value of k. Notice that the correlation structure of the data is preserved by this procedure. For each value of k, determine different percentiles (1%, 5%, 
10%, 50% etc.) of the corresponding histogram. (See the bottom diagrams in 
Supplementary Fig. 1.)  
•  Compare the actual signal-to-noise scores with the different significance levels obtained for 
the histograms of permuted class labels for each value of k. This test helps to assess the 
statistical significance of gene markers in terms of the distribution of class-gene scores 
using permuted labels. 
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Supplementary Figure 1: Neighborhood Analysis 
In Sheets A and B (AML vs. Neut. (HuFL) and AML vs. Mono. (HuFL), respectively) of the 
Supplementary Data Excel Worksheet, the values for permutation tests of marker genes are 
reported in tables with the following format.  The Distinction column represents the class for 
which the markers are high (low in the other classes). The Distance column is the signal-to-
noise to the actual phenotype. The Permutation  20% columns represent the percentile 
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(significance level) in the histograms of signal to-noise scores for permuted labels for a given 
value of k. The Feature column is the gene accession number and the Description column is the 
gene name.  
Two thousand five hundred permutations were performed to identify the differentiation signature 
genes that met statistical significance at the 80th percentile using GeneCluster2 
(http://www.broad.mit.edu/cancer/software/software.html). We chose marker genes from 
amongst this list; achievement of higher levels of statistical significance was restricted by data 
set size.  In addition, Glyceraldehyde 3-phosphate dehydrogenase (GAPD) was selected as the 
control gene based on the Affymetrix expression data and historical use of GAPD as a control. It 
showed minimal variation across the microarray data set. In the actual screen, this control gene 
was used to filter out chemicals that killed the cells, to filter out wells where, for technical 
reasons the experiment did not work, and to normalize for well to well and plate to plate 
variability in total amount of material as discussed below in Part II Small Molecule Library 
Screen: Data Analysis. 
B. Confirmation of Signatures in an HL-60 Cell Line 
In Vitro Differentiation and Preparation for Microarray Analysis  
HL-60 cells (American Type Culture Collection) were maintained in culture in RPMI 1640 
(Cellgro) with 10% fetal bovine serum (Sigma) and 1% penicillin-streptomycin (Cellgro). In a 
duplicate experiment, HL-60 cells were differentiated to neutrophils with 1 µM all trans retinoic 
acid (ATRA) (Sigma) for 0, 24, 72, and 120 hours. Differentiation was confirmed with 
examination of morphology after May-Grunwald-Giemsa staining. Maximum differentiation was 
seen at 5 days. HL-60 cells were stimulated to differentiate to a monocyte-macrophagelike cell, 
in duplicate, with 10 nM phorbol 12-myristate 13-acetate (PMA) (Sigma) for 0, 4, 12, and 24   9
hours. Differentiation was confirmed by examination under light microscopy. PMA differentiated 
cells became flattened, adherent to the cell culture dish, and developed pseudopods. Nearly all 
cells appeared to be differentiated by 24 hours. RNA was extracted from the cells at each point 
in the time course. This RNA was then prepared for hybridization to Affymetrix HuFL 
microarrays. Data were scaled and filtered as described above; the scaled data are contained in 
Res File 2, HL60_undiff_PMA_ATRA.res. 
Microarray Data Analysis 
We confirmed that the expression signatures characterized for primary AML cells versus normal 
monocytes or neutrophils could also distinguish an undifferentiated HL-60 cell from a PMA 
differentiated or ATRA differentiated HL-60 cell, respectively. We used the SNR statistic to rank 
the genes that distinguished the untreated HL-60 cells from the ATRA or PMA treated HL-60 
cells. Genes meeting statistical significance in both the primary cells and the HL-60 model of 
differentiation were chosen as candidate markers. To further refine this list, we performed the 
following analysis. A supervised vector was created representing an idealized signature gene, 
whereby expression was low in the primary AML cells, high in purified neutrophils, and showed 
increasing levels of expression in 5 day time-course of ATRA-treated HL-60 cells.  Next, the 
genes were ranked according to their similarity to this supervising vector, using normalized gene 
expression values and Euclidean distance as the metric.  The genes topping this list 
represented potential candidate genes for use in the screen.  Next, these candidates were 
examined by eye for their being expressed at low absolute levels in the undifferentiated state 
because some of the markers showed relative up-regulation, but were nonetheless highly 
expressed in the undifferentiated cells.  Candidate genes with robust induction (i.e. high fold-
induction) were similarly given highest priority.  Such high priority genes were then brought 
forward to multiplexed RT-PCR testing.  The 5 genes constituting the differentiation signature   10
represented the first 5 genes that exhibited robust differential expression as detected by 
multiplexed RT-PCR and SBE/mass spectrometric detection.  The gene selection process was 
therefore somewhat ad hoc, and future screens would likely benefit from a more systematic and 
automated approach to marker selection and testing. The genes selected include Interleukin 1 
receptor antagonist (IL1RN) and Secreted phosphoprotein 1 (SPP1) for the monocyte signature 
genes and Autosomal chronic granulomatous disease protein (NCF1) and Orosomucoid 1, or 
α1acid glycoprotein, (ORM1) for the neutrophil signature genes. (See Sheets C and D (Undiff. 
HL60 vs. ATRA and Undiff. HL60 vs. PMA, respectively) of the Supplementary Data Excel 
Worksheet) 
C. High Throughput RT-PCR Signature Gene Amplification 
Cell culture and RT-PCR were converted to a 384-well format. HL-60 cells were grown in 384- 
well culture plates in 40 µl of medium (RPMI 1640 with 10% fetal bovine serum and 1% 
penicillin-streptomycin) at 0.45 x 10
6 cells/ml concentration. Cells were lysed with 45 µl/well of a 
mixture containing a hypotonic, detergent-containing solution, DTT, and RNAse inhibitor. We 
assessed for genomic DNA contamination by PCR for genomic DNA sequence in the absence 
of a reverse transcription reaction and found no evidence of contamination (data not shown). 15 
µl of lysate and 6 µl of a 2.5X binding buffer were then transferred to a 384-well plate coated 
with oligo-dT. The polyA tails of mRNA bind to the oligo-dT on the plate during a 15 minute 
incubation. The wells were washed twice with a low salt buffer and reverse transcription was 
performed using the oligo-dT as a primer in a 20 µl M-MuLV reaction at 37
o C for 1.5 hours. 
Thus, the single stranded cDNA was covalently linked to the plate via the oligo-dT primer. 
These cDNAs were subsequently used in a multiplexed PCR reaction. Lysis buffers, 384-well 
custom coated oligo-dT plates, wash buffers, and M-MuLV were purchased from Pierce and 
used in a modified version of their Express Direct mRNA Capture and RT-PCR system. We   11
currently obtain oligo-dT coated 384-well plates and lysis buffers from RNAture (Irvine, CA).  
PCR primers were designed with Primer 3 software (http://www.broad.mit.edu/cgi-
bin/primer/primer3_www.cgi). To eliminate the possibility of amplifying contaminating genomic 
DNA, PCR primers were designed to span a large intron. Primers contained 19-22 sequence 
specific nucleotides and a tag of nonspecific sequence (9-23 nucleotides). The addition of a tag 
prevents PCR primers from interfering with the assessment of SBE/MALDI-TOF data (see 
below). Amplicons were 120-385 nucleotides in size. PCR was performed with the following 
reagents and conditions: 1X PCR buffer (Perkin Elmer), 5 mM MgCl2, 2.5 mM dNTPs, 0.05 uM 
each primer, and 0.15 units/rx Taq polymerase (AmpliTaq Gold, Perkin Elmer). In an MJ 384-
well thermocycler, samples were incubated at 92
o C for 9 minutes and then 30 cycles of 92
o C 
for 30 sec, 65
o C for 30 sec, and 72
o C for 1 min were performed. A final extension of 72
o C for 5 
minutes completed the PCR.   12
Supplementary Table 1: Marker Gene PCR Primer Sequence 
PCR Primers: 
Gene Name (GenBank 
number) Primer  Sequence 
 
Glyceraldehyde 3- 
dehydrogenase (M33197)   
GAPD FT7  TAATACGACTCACTATAGGGAGAAGCCACATCGCTCAGACAC 
GAPD RT3  AATTAACCCTCACTAAAGGGAGACTCCATGGTGGTGAAGACG 
 
Interleukin 1 receptor 
antagonist (X53296)   
IL1RN FT7  TAATACGACTCACTATAGGGAGACTGGGATGTTAACCAGAAGACC 
IL1RN RT3  AATTAACCCTCACTAAAGGGAGAAGCTGGAGTCTGGTCTCATCA 
 
Secreted phosphoprotein 1 
(U20758)   
SPP1 FT7  AGCGGATAACGCCTTCTCAGCCAAACGCCG 
SPP1 RT3  AGCGGATAACGCCTTGGAAGGGTCTGTGGGGC 
 
47 kD Chronic granulomatous 
disease protein (M55067)   
NCF1 FT7  AGCGGATAACAGTCCTGACGAGACGGAAGA 
NCF1 RT3  AGCGGATAACCGTCCAGGAGCTTGTGAATTA 
 
Orosomucoid (X02544)  
ORM1 FT7  TAGGTTGACAAGCTCTCGACTGCTTGTGC 
ORM1 RT3  TAGGTTGACCTCTCCTTCTCGTGCTGCTT 
 
D. Signature Gene Detection 
PCR amplicon detection was accomplished using single base extension (SBE) matrix-assisted 
laser desorption/ionization time-of–flight (MALDI-TOF) mass spectrometry. 5 µl of PCR product 
was treated with 0.3 units of shrimp alkaline phosphatase (Sequenom) to inactivate any 
remaining dNTPs (34
o C X 20 min; 85
o C X 5 min). SBE probes were 16-21 nucleotides in size 
with an annealing temperature of 50-55
o C and sequence complementary to the PCR amplicon   13
of interest. We then performed a 5-plex SBE reaction in a 9 µl reaction volume with 1x 
Thermosequenase buffer, 2.7 µM of each primer, 0.2 mM of each ddNTP (Sequenom), and 0.58 
units/rx of Thermosequenase (Sequenom) in an MJ 384-well Thermocycler (92
o C X 2 min, 40 
cycles of 92
o C X 20 sec, 50
o C X 30 sec). The SBE product was then treated with a cation resin 
(Sequenom) to remove residual salt from the reaction. The purified extension product was then 
loaded onto a matrix pad (3-hydroxypicolinic acid) of a SpectroCHIP (Sequenom) with a 
Spectropoint robot (RoboDesign). SpectroCHIPs were analyzed using a Bruker Biflex III MALDI-
TOF mass spectrometer (SpectroREADER) and spectra processed using SpectroTYPER 
software (Sequenom). For each extension fragment, there is a peak intensity at the expected 
mass corresponding to the amount of that fragment and a signal-to-noise ratio (SNR) is 
calculated correcting this intensity for background noise.   
Supplementary Table 2: SBE Probe Sequence 
SBE Probe   Probe Sequence  Terminator  
GAPD_T ATGGGGAAGGTGAAGG  T 
IL1RN_T CATTGAGCCTCATGCTC  T 
SPP1_G TACAACAAATACCCAGATGCT  G 
NCF1_G AAGGCCTACACTGCTGTG  G 
ORM11_C CCCAGGTCAGATGTCATGTA  C 
 
Supplementary Fig. 2 below illustrates the correlation between the PCR amplicon abundance 
and that estimated by mass spectrometry. PCR product from GAPD was serially diluted 2-fold 
into an SBE reaction and then evaluated by MALDI-TOF mass spectrometry.  Each dilution 
point represents 19 replicates.  
Supplementary Figure 2: Linear Relationship Between PCR Amplicon and Mass Spectrometric 
Measurement of SBE Product 
Part II: Small Molecule Library Screen 
A. Library Description 
We used a library enriched with compounds with known mechanisms of action and containing 
many FDA approved drugs
3. The library contained 1739 compounds and was assembled from 
three sources i) compounds from Sigma Corporation with annotation describing biological 
activity, ii) a set of FDA-approved small molecule drugs, and iii) a library of 640 
pharmacologically active compounds (LOPAC) sold by RBI, a subdivision of Sigma Corporation. 
Compounds in group (i) were selected by attempting to identify compounds in the Sigma 
catalogue documented to have biological activity. In cases where dozens of close analogs or 
salt forms of a compound were available, one to three representative members of the 
compound class were selected. The FDA-approved drugs in group (ii) were selected with the 
Electronic Orange Book list that is maintained by the FDA and lists all approved drug products 
4. 
As of November 1999, there were 19,299 products approved by CDER (Center for Drug 
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Evaluation and Research within the FDA), including over the counter medications, prescription 
drugs and discontinued products. However, many of these products are alternative doses of the 
same active ingredient or different salt forms of the same active compound. By eliminating such 
redundancies, the list was reduced to 1,320 distinct small molecule FDA-approved drugs. 708 of 
these drugs (54%) were purchased from Sigma, Aldrich, RBI and Fluka. Compounds in group 
(iii) were purchased from RBI as a set of 640 compounds. The compounds were dissolved in 
dimethylsulfoxide (DMSO) at a concentration of 4 mg/ml and formatted in 384-well plates for 
screening. The library also contained 181 wells with 0.1% DMSO only for a total of 1920 wells. 
A list of the compounds in the library is located in Supplementary Data Excel File, Sheet E, 
Compound Library. 
B. Screening Methods 
HL-60 cells were grown at 0.45 x 10
6 cells/ml in 40 µl, in 384-well culture plates. On each plate, 
there were 16 wells with the following controls: medium only, undifferentiated, 10 nM PMA 
differentiated, and1 µM ATRA differentiated HL-60 cells. The remaining wells each contained a 
compound from the library. 40 nl of compound was transferred from a stock collection of 4 
mg/ml for a final concentration of 4 µg/ml. For an average compound with a MW=400, the final 
concentration would be 10 µM. At three days, RNA was extracted and 20 µl RT-PCR performed 
in high throughput as described above with 5 primer pairs: GAPD, IL1RN, SPP1, NCF1, and 
ORM1. Five percent of the wells from each plate were evaluated by gel electrophoresis to 
confirm that negative control wells were appropriately negative and that the PCR had worked as 
expected in the positive controls. Then, PCR product was detected after a 5-plex single base 
extension reaction and MALDI-TOF mass spectrometry as described above. 
   16
C. Data Analysis  
We developed an analysis pipeline containing several algorithms to identify and prioritize likely 
differentiating chemicals. These algorithms combined the data across triplicate replicates for 
each chemical well in the library and utilized the controls in each plate. The SNR generated by 
SBE MALDI-TOF mass spectrometry, as described above, was used as a proxy for the gene 
expression level of each of the five genes. We used the expression ratio, gi/gGAPD where gi = the 
SNR level of the signature gene and gGAPD = the SNR level of GAPD, to achieve maximal 
consistency across and within plates.  The analysis pipeline consisted of several steps as 
detailed below: 1. Filtering of wells containing significant cell death, 2. Normalization of plate to 
plate expression levels, 3. Threshold-based analysis, 4. Probability-based analysis, and 5. Final 
Neutrophil and Monocyte Score calculation. 
Filtering 
This step was designed to eliminate dead wells from further analysis. We used GAPD values as 
a proxy for cell viability. Because ratios with GAPD as the denominator were used for 
subsequent analysis, we needed to eliminate wells where GAPD was nominally zero with some 
measurement noise. Forming a ratio with such a low denominator would potentially falsely flag a 
well where the cells were merely dead or dying.   
One standard deviation above the mean of the GAPD SNR for the water control wells was 
calculated. Wells falling below this value were eliminated from further analysis. After filtering 
was complete, all subsequent analysis used a ratio of the readout genes (NCF1 and ORM1 for 
neutrophil signature and IL1RN and SPP1 for the monocyte signature) to the reference gene 
(GAPD), the expression ratio. 
   17
Normalization 
This step was applied to correct for plate to plate variability. We found the median expression 
ratio for each marker gene for the positive controls on each plate (Xij where i=plate number and 
j=marker gene). Next, we scaled all of the plates by multiplying each expression ratio j on plate i 
by 1.5/Xij. 
Threshold-Based Analysis 
We explored a combination of two methods to identify candidate differentiating agents. The first 
method used a threshold-based analysis. For each marker gene expression ratio, a threshold 
distinguishing undifferentiated versus differentiated was established using the untreated and 
monocyte or neutrophil differentiated positive controls. These thresholds were optimized using a 
recursive algorithm to correctly identify the controls as undifferentiated, monocyte differentiated, 
or neutrophil differentiated. Each compound was scored for each marker gene to determine the 
number of measurements for the triplicate replicate above the established threshold.  
Probability-Based Analysis  
This approach converted the normalized expression ratios into a measure of the likelihood of 
the well containing differentiated cells. The basis of the probability model was a Gaussian 
density model for each gene where the Gaussian density parameters (mean and standard 
deviation) were learned using the measured log-gene expression ratios from the untreated HL-
60 control wells. We used log-expression ratios because they better fit the symmetric Gaussian 
distribution. Our analysis focused on the cumulative probability that a well was undifferentiated. 
This was calculated by integrating the Gaussian density from the observed log-expression ratio 
(X0) for each chemical well to plus infinity (see Supplementary Fig. 3). For each gene, this 
procedure gave a value that a given well was undifferentiated. Rather than work directly with probabilities, we calculated the following probability score metric:    ⎟
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Supplementary Figure 3: Cumulative Probability Distribution 
This probability score gives “votes” from each piece of information and varies between negative 
infinity and plus infinity. In practice, we applied a maximum (0.999) and minimum (0.001) limit to 
avoid infinity. A probability that a well is undifferentiated gives a highly negative score, a 
probability near 0 gives a high positive score, and a probability of 0.5 gives a score of 0. The 
Supplementary Fig. 4 below shows a plot of the score as a function of probability.  For each 
marker, the average probability score across three replicates was calculated.  
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Supplementary Figure 4: Plot of the Probability Scoring Function 
Final Monocyte and Neutrophil Score Calculation 
This metric sought to capture both the threshold-based and the probability-based statistics in 
one score. A final Monocyte Score was calculated for each well by first taking the sum of the 
IL1RN and SPP1 probability scores.  This value was then multiplied by the total fraction of 
measurements above threshold for IL1RN and SPP1.  
() 1 1 *
6
Score   Monocyte SPP RN IL S S
F
C
+
−
=  
where C is the total number of IL1RN and SPP1 expression ratios above threshold, F is the 
number of replicates filtered for this compound, and Sj is the probability score metric for the 
marker gene j.  In a similar manner, the Neutrophil Score was calculated for the marker genes 
NCF1 and ORM1. 
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D. Compound Hit Selection 
The distribution of the Neutrophil Scores for the test compounds was compared to that of the 96 
negative control HL-60 wells. Pearson's chi-square analysis was used to evaluate whether the 
tails of the Neutrophil Score distribution were significantly different for the compound treated 
and negative control wells.  A 2 x 2 contingency table was created by categorizing both 
untreated and treated samples according to their Neutrophil Scores by designating wells with 
scores less than 0.4 as undifferentiated and scores greater than or equal to 0.4 as 
differentiated.  The contingency table was evaluated in S-Plus (http://www.mathsoft.com/splus) 
using the Pearson's chi-square test with Yates' continuity correction.  We used the chi-square 
test to test the hypothesis that the proportion of differentiated wells is the same for the treated 
and negative control wells.  A similar analysis was performed for the Monocyte Score using a 
cutoff of 0.1 for the differentiated designation (Supplementary Data Excel File, Sheet F, Score 
Distributions). 
We prioritized 15 top scoring compounds by using a combination of selection strategies. Eight 
compounds were selected from those with top scores based on the Monocyte Score and 
Neutrophil Score. We also evaluated compounds with high performance at a single marker 
gene. Six compounds were selected from those with two or more replicates passing threshold 
and high probability-based scores for the marker gene NCF1. For several compounds, all three 
replicates passed threshold.  
One compound, 4,5-dianilinophthalimide,  was selected based on high performance utilizing an 
alternative signature detection method.  In the process of developing the mass spectrometric 
detection method, we explored other detection methods. Although we believe the mass 
spectrometric detection is a superior system, one of the alternative methods yielded the 
compound  4,5-dianilinophthalimide.  This method is the reverse of traditional cDNA arrays in   21
which probes are spotted onto a slide and the samples hybridized to the probes. Here, 
unpurified, multiplexed PCR amplicons were spotted via a Genetix spotter onto an aminosilane-
coated microscope slide in duplicate. The spotted DNA was UV cross-linked and the slides 
boiled in sterile water for two minutes to denature the PCR duplex. The genes specific for each 
differentiated phenotype, and the control gene GAPD, were detected with a 2-step fluorescence 
signal amplification staining procedure using DNA dendrimer probes. The 3DNA dendrimer is a 
complex of DNA duplexes with an end-labeled fluorescent moiety (ALEXA, CY3, or CY5). The 
3DNA dendrimer contained a sequence that is captured by a bipartite probe. The bipartite probe 
had sequence complementary to the PCR amplicon of interest and a dendrimer capture 
sequence.  In the first hybridization step, 4 bipartite probes per gene were hybridized to the 
microarray and the slide incubated at 45º C for 45 minutes with a coverslip in a humidifying 
chamber. The slides were washed and hybridized with the 3DNA dendrimer during a 45 minute 
incubation at 45º C. The slides were then washed, dried by centrifugation, and scanned using a 
GSI 5000 scanner. Arrayvision software extracted the scanned image. Data was processed in a 
similar manner to that generated by mass spectrometry. While this method could be performed 
at a lower cost, there was higher background noise and lower reproducibility than mass 
spectrometric PCR amplicon detection.  
The complete list of prioritized compounds further characterized is shown in Supplementary 
Table 3.   22
Supplementary Table 3: Compound Hits 
Aminopterin     
R-(-)-Apomorphine HCl   
8-(3-Chlorostyryl)caffeine   
Cyclazosin HCl     
4,5-Dianilinophthalimide    
Dimaprit dihydrochloride     
Erythro-9-(2-hydroxy-3-nonyl)adenine HCl 
5-Fluorouracil     
5-Fluorouridine     
16-Ketoestradiol     
α-Methyl-L-p-tyrosine     
Pergolide methanesulfonate     
1,10- Phenanthroline      
(-)Scopolamine methyl bromide   
Sulmazole     
 
Part III: Confirmation of Hits 
A. Signature Gene Evaluation 
HL-60 cells, in triplicate, were treated for 5 days with compound hits at the following 
concentrations based on preliminary experimental evaluation of differentiation and growth 
inhibition (data not shown): 5 µM R-(-)-apomorphine HCl, 75 µM 8-(3-chlorostyryl) caffeine, 7.5 
µM cyclazosin HCl, 30 µM 4,5-dianilinophthalimide, 70 µM erythro-9-(2-hydroxy-3-nonyl) 
adenine HCl, 1 µM 5-fluorouracil, 0.1 µM 5-fluorouridine, 70 µM 16-ketoestradiol, 100µM α-
methyl-L-p-tyrosine, 50 µM pergolide methanesulfonate, 0.8 µM 1,10-phenanthroline, 75 µM (-) 
scopolamine methyl bromide, and 70 µM sulmazole. Compounds were all purchased from 
Sigma with the exception of cyclazosin that was kindly provided by Dr. Dario Giardina. We also 
included untreated, 0.1% DMSO, 1 µM  ATRA, 10 nM PMA, and 0.1 µM 1,25-dihydroxyvitamin   23
D3 treated controls. RNA was extracted and prepared for hybridization to Affymetrix HG-U133A 
microarrays containing 22,283 genes and ESTs as described above. Nine primary patient AML 
samples obtained from the Cancer and Leukemia Group (CALGB) leukemia bank and three 
normal monocyte and neutrophil samples (described above) were also included in this data set. 
Expression values were calculated using GeneChip MAS5 software (Affymetrix). All expression 
files in a given experiment were scaled to a reference file (the file found to have the median 
value of expression) based upon the mean expression value for all genes present on the 
microarrays.  A floor of 10 and a ceiling of 16,000 were used. Only genes with a 5-fold variation 
in expression across the data set and a minimum absolute difference of 50 were considered. 
These scaled data are available in Res File 3, Myeloid_Screen_Compound_Eval.res.  
HuFL Affymetrix accession numbers for the marker genes were mapped to Affymetrix U133A 
accession numbers using Affymetrix's Array comparison worksheets (available at 
http://www.affymetrix.com/support/technical/comparison_spreadsheets.affx).  Because there 
was no direct map from HuFL to U133A, we mapped HuFL accession numbers to U95A 
accession numbers using the 'HuGeneFL to Human Genome U95A' map and then mapped the 
U95A accession numbers to U133A accession numbers using the 'Human Genome U95 to 
Human Genome U133, Best Match' map (see Supplementary Table 4). We compared the 
mean expression value for each marker gene in the negative controls (untreated and 0.1% 
DMSO vehicle treated HL-60 cells) to that in the chemical treated HL-60 samples. For each 
marker gene, we evaluated the fold induction and estimated statistical significance with a one-
tailed T-test assuming two samples with unequal variance. Chemicals were considered 
confirmed hits if the mean fold change was 2-fold or greater and if the P-value was less than 
0.05 on T-test analysis for the marker gene (Supplementary Data Excel File, Sheet G, Marker 
Gene Confirm).   24
 
Supplementary Table 4: Affymetrix Accession Number Mapping 
Marker Gene  HuFL Probe Set  U95A Probe Set  U133A Probe Set 
IL1RN X53296_at 37603_at  212657_s_at 
SPP1 U20758_at  2092_s_at  209875_s_at 
NCF1 M55067_at  40159_r_at  214084_x_at 
ORM1 X02544_at 35315_at 205040_at 
 
B. Analysis of Whole Genome Effects of Chemicals  
Mantel Test Analysis 
We used a Mantel test to assess whether the chemicals induced changes on a whole genome 
level consistent with differentiation.  A Mantel test is a non-parametric, randomization-based 
procedure that estimates the correlation between two distance matrices 
5.  The Mantel test was 
initially used to study the correlation in the temporal and spatial distributions of cancer 
incidences.  Since then, there has been a large body of work that has employed this statistic in 
the analysis of autocorrelated interactions, especially in the fields of ecology, vegetation 
science, and epidemiology.  Because the Mantel test is non-parametric, it can be used to test 
relationships between data sets that may not be totally independent, unlike more commonly 
used measures such as the least squares regression and the chi-square test. This characteristic 
of the Mantel test makes it particularly useful in the analysis of biological data sets where many 
factors can influence observed phenotypes. 
For this work, we used the Mantel test to compare sets of primary AML versus the normal 
mature myeloid samples to sets of undifferentiated versus compound treated HL-60 cells 
according to their level of expression to see if genes across the whole genome were being up-regulated and down-regulated similarly.  Specifically, we compared the expression patterns 
(measured on Affymetrix’s U133A microarray) observed in data sets composed of 9 primary 
AML versus three mature myeloid samples to those expression patterns observed in data sets 
composed of 12 untreated samples versus the three compound treated samples for each of the 
selected compounds.  For a given gene expression data set X and its corresponding class 
labels, the distance of each feature from the class labels was calculated using the signal-to-
noise statistic.  The signal-to-noise statistic is calculated as follows: 
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where µi1 represents the mean expression of samples from class 1 for feature i and σi1 
represents the standard deviation of class 1 for feature i.  Similarly, the signal-to-noise statistic 
is calculated for the second set of samples Y.  The elements of vector X and vector Y 
correspond to the same set of objects (U133A probe sets).  The Pearson correlation was 
computed between the corresponding elements of the two vectors to produce the Mantel 
correlation Rm.  The Pearson correlation was calculated as follows: 
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. 
where Xi is the signal-to-noise statistic for feature i of sample set X and Yi is the signal-to-noise 
statistic for feature i of sample set Y.  The Mantel correlation Rm was used as the reference 
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value in the Mantel test.  To calculate the significance level, the elements of one of the vectors 
were randomly permuted to produce a permuted vector X*.  As before, the Mantel statistic Rm*  
was computed between X* and Y.  The permutation-computation steps were repeated 2500 
times and the resulting distribution was used to estimate the P-value by examining the 
proportion of Rm* values that are greater than Rm.  This procedure was repeated for each of the 
selected compounds (Supplementary Data Excel File, Sheet H, HL-60 Mantel Test). 
Identification of Gene Induction Associated with Differentiation 
Using the above data set, the signal-to-noise ratio was used to rank the genes distinguishing the 
9 primary AML samples from the mature monocytes and the mature neutrophils. The top 100 
genes with a P-value of 0.01 on permutation testing (2500 permutations) were identified 
(Supplementary Data Excel File, Sheets I and J, AML vs. Neut. (U133A) and AML vs. 
Mono. (U133A)).  We then projected this list of genes in the space of the undifferentiated 
versus chemical treated HL-60 cells positively correlated with the differentiated state by the 
Mantel test. We used the signal-to-noise ratio to rank order these genes. We projected the top 
25 genes in each direction onto a heat map. We then projected these genes in the space of 
undifferentiated HL-60 cells versus ATRA, 1,25-dihyroxyvitamin D3, and PMA treated HL-60 
cells. 
Gene Overlap Analysis in Selected Compounds 
Because the Mantel test does not reflect the potency of gene expression changes induced by 
the candidate compounds, we also performed an alternate method of comparing whole genome 
effects that compared the regulation of individual genes for the 8 selected compounds to that of 
the reference compounds and primary cells.  Supplementary Data Excel File, Sheet K, Gene 
Overlap Analysis, summarizes the results from this whole genome comparison.  This analysis   27
used the data file Myeloid_Screen_Compound_Eval.res that contained all samples. We first 
selected the subset of three normal human neutrophil and 9 primary patient AML samples, 
applied thresholding (10 minimum and 16,000 maximum) and filtering (5-fold minimum 
difference and 50 minimum absolute difference), and found the genes that were significantly 
regulated at the 1% level using GeneCluster2 with 1000 permutations and the mean-based 
signal-to-noise statistic (see Part 1 - Section A for a description of the calculation of the signal-
to-noise statistic).  10,048 of 22,283 genes were significant at the 1% level.  We then followed a 
similar procedure to find the subset of those 10,048 genes that were significant at the 1% level 
in the 12 untreated versus three ATRA treated HL-60 samples.  1143 genes were significant at 
the 1% level in both the AML versus neutrophil distinction and the untreated versus ATRA 
treated distinction.  We then performed a two-tailed T-test in Microsoft Excel for each of the 8 
sets of compound treated samples versus the untreated HL-60 samples for each of the 1143 
genes.  Supplementary Data Excel File, Sheet K, Gene Overlap shows which genes were 
significantly regulated for each of the selected compounds and summarizes the fraction of the 
1143 genes that were significant at the 5% level for each of the selected compounds.  
C. NBT Reduction Assay 
HL-60 cells were exposed to chemicals confirmed to overexpress the differentiation marker 
genes at the concentrations described above. Experiments were performed in triplicate. Nine 
untreated and 9 DMSO treated HL-60 cell negative control samples were evaluated. At 6 days, 
an NBT reduction assay was performed.  Cells were incubated at 37º C for 1 hour in a mixture 
containing total medium, 0.1% NBT (Sigma), and 1µg/ml TPA (Sigma).  The percentage of blue 
cells was counted by light microscopy for at least 200 cells per sample. Untreated cells were 
compared to chemical treated cells with a one-tailed T-test analysis assuming two samples with 
unequal variance. The untreated cells were not statistically different from the DMSO treated   28
samples. 
D. Phagocytosis Assay 
HL-60 cells were exposed for 5 days to chemicals confirmed to overexpress the differentiation 
marker genes at the concentrations described above. Experiments were performed in replicates 
of 5. Untreated and vehicle treated HL-60 cell negative controls were also evaluated. Cells were 
incubated for one hour with 0.026% fluorescent latex beads (Fluoresbrite Carboxylate 0.75 
micron microspheres, Polysciences) and then washed three times with PBS. Fluorescent uptake 
was then analyzed by FACS with a Becton Dickinson FACScan and CELLQuest analytical 
software. Laser excitation of 488nm was used and fluorescent emission of 530/30 nm band 
pass detected. First, cells without beads established the gate for live cells using forward and 
side scatter patterns. Next, cells incubated with beads were used to establish the fluorescent 
intensity background. Compound treated cells were then compared against this background. An 
M1 gate was set at 5% for the untreated and vehicle treated control cells. We then evaluated 
the percent of cells above this gate for the compound treated cells. An average of the 5 
replicates was taken. In a one-tailed T-test the mean of the untreated or vehicle treated controls 
was compared to the chemically treated cells assuming two groups with unequal variance. 
Results for candidate compounds and ATRA and 1,25-dihydroxyvitamin D3 controls are shown 
in Supplementary Fig. 5a below (a = (R)-(-)-apomorphine HCl, b = 4,5-dianilinophthalimide, c = 
erythro-9-(2-hydroxy-3-nonyl) adenine HCl, d = 5-fluorouridine, e = 16-ketoestradiol, f = 
pergolide methanesulfonate, g = cyclazosin HCl, h = 1,10-phenanthroline,  i = ATRA,  j = 1,25-
dihydroxyvitamin D3) .The red spectra represents the untreated controls and the black the 
chemically treated cells.  
  
Supplementary Figure 5a: Phagocytosis Analyzed by FACS 
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Deconvolution microscopy confirmed that the fluorescent beads were indeed intracellular and 
not simply decorating the cell.  Shown in Supplementary Fig. 5b is an HL-60 cell treated with 
25 uM 4,5-dianilinophthalimide for three days and incubated with fluorescent beads. Images 
were obtained with a Zeiss Axiovert microscope and fluorescent image deconvolution with 
SlideBook 3I software. 3-D reconstruction was performed with Volocity software using two 
channels (FITC and Brightfield).   
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Supplementary Figure 5b: Phagocytosis Analyzed by Fluorescent Microscopy 
E. Propidium Iodine (PI) Assay Determination of IC50 
A PI cell growth and cytotoxicity assay was performed according to the protocol described in 
Cell Biology: A Laboratory Handbook
6 to determine the inhibitory concentration 50% (IC50) of 
the chemical hits. When possible, chemical stocks were suspended in water. Otherwise, they 
were suspended in the minimum concentration of ethanol or DMSO to obtain solubility. DMSO 
and ethanol had no effects on cell growth in the concentration of diluent used in the subsequent 
experiments (data not shown).  
HL-60 cells were plated in 100 µl of RPMI 1640 (Cellgro) with 10% fetal bovine serum (Sigma) 
and 1% penicillin-streptomycin (Cellgro) at 100,000 cells/ml. Chemical hits were evaluated in 
triplicate in a 2-fold dilution series starting at a maximum concentration of 100 µm. Chemical + 
medium only control wells (no cells) were included as controls. Chemical treated HL-60 cells 
were compared to 7 untreated HL-60 cell control wells. HL-60 cells were incubated for 0 and 5 
days in a 37º C incubator. They were then frozen for a minimum of 12 hours at -20º C wrapped 
in Parafilm. At the time of assessment, plates were thawed at 50º C for 15 minutes. 50 µl of 200 
µg/ml propidium iodine solution (Sigma) was added for a final concentration of 40 µg/ml. Plates 
were incubated in the dark for one hour at room temperature. PI fluorescence was then read in 
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a BioLum 960 plate reader using a 530-nm excitation filter and a 620-nm emission filter. To 
determine the IC50, the following calculations were performed: 
1.  For time 0, the average no cell control values of fluorescence were subtracted from the 
cell values to determine the amount (Z) of cellular polynucleic acid (PNA) (DNA + RNA) 
present at the beginning of the chemical incubation period.  
2.  For time 5 days, the average no cell control values were subtracted from the average 
untreated cell values to determine the amount (C) of cellular PNA present in the 
untreated cells at the end of chemical incubation period. 
3.  For time 5 days, the average chemical blank value (no cells) was subtracted from the 
average end of assay test values (cells incubated with chemicals) to determine the 
amount (T) of cellular PNA present in the test cultures at the end of the chemical 
incubation period. 
4.  The IC50 is the growth inhibitory concentration of a chemical that reduces the (T-Z) to 
50% of (C-Z)    32
Supplementary Table 5: Compound IC50 
Compound Name    IC50 
R (-) - apomorphine HCl    3.8 µM 
8-(3-chlorostyryl) caffeine    > 100 µM 
cyclazosin HCl    7.3 µM 
4,5-dianilinophthalimide    5.5 µΜ 
erythro-9-(2-hydroxy-3-nonyl) adenine HCl  > 100 µM 
5-fluorouracil    6.6 µM 
5-fluorouridine   29.8  nM 
16-ketoestradiol    > 100 µM 
α-methyl-L-p-tyrosine    > 100 µM 
pergolide methanesulfonate    62.9 µM 
1,10-phenanthroline     2.4 µM 
(-) -scopolamine methyl bromide    > 100 µM 
sulmazole    > 100 µM 
 
F. U937 Cell Analysis 
U937 cells (American Type Culture Collection) were treated in duplicate with compounds as 
follows: 5 µM R-(-)-apomorphine HCl, 7.5 µM cyclazosin HCl, 70 µM erythro-9-(2-hydroxy-3-
nonyl) adenine HCl, 0.1 µM 5-fluorouridine, 70 µM 16-ketoestradiol, 50 µM pergolide 
methanesulfonate, and 0.8 µM 1,10-phenanthroline. 1µM ATRA and 0.1 µM 1,25-
dihydroxyvitamin D3  were used as positive controls. At 5 days, May Grunwald Giemsa staining 
was performed after cytospin preparation. At the above tested concentrations, cyclazosin HCl 
and 1,10-phenanthroline killed the cells.  Erythro-9-(2-hydroxy-3-nonyl) adenine HCl and 5-
fluorouridine induced morphological changes consistent with macrophage differentiation and 
ATRA induced changes consistent with neutrophil differentiation. The remaining compounds did   33
not induce striking morphology changes. We next performed a phagocytosis assay in duplicate 
at 6 days as described above.  Erythro-9-(2-hydroxy-3-nonyl) adenine HCl and 5-fluorouridine 
induced significant phagocytosis (P < 0.001) as did 1,25-dihydroxyvitamin D3 (P = 0.02).  Data 
are shown in Supplementary Data Excel File, Sheet L, U937 Phagocytosis. NBT reduction 
was induced only for the ATRA treated cells.  
G. Primary Patient AML Cell Analysis 
Patient-derived AML samples from the Children’s Hospital of Boston were obtained with Internal 
Review Board (IRB) approval and parent/patient informed consent at time of diagnosis. One 
sample was from a leukopharesis of a patient with acute promyelocytic leukemia (APL) with a 
t(15;17) and a white blood cell count of 185,000 with 97% myeloblasts at diagnosis.  The other 
sample was from the peripheral blood of a patient with M1-AML with a white blood cell count of 
37,200 with 74% percent myeloblasts. Samples were processed with Ficoll-Paque separation. 
For the primary APL sample, cells were treated in duplicate with 1 µM ATRA, 70 µM 16-
ketoestradiol, 25 µM 4,5-dianilinophthalimide, 70 µM erythro-9-(2-hydroxy-3-nonyl) adenine HCl, 
and 1 µM 1,10-phenanthroline and evaluated with May-Grunwald-Giemsa staining daily.  At 5 
days, RNA was extracted from these samples along with two untreated controls and prepared 
for hybridization to HG-U133A Affymetrix microarrays as described above. Preprocessing of the 
data included establishing a floor of 75 and a ceiling of 16,000; a variation filter with a minimum 
of 5-fold change was applied.  The Mantel test was performed to evaluate the whole genome 
effects of the compounds on primary APL cells (Scaled data are in Res File 4, 
Myeloid_APL_compound_eval.res; Mantel test results are in Supplementary Data Excel 
File, Sheet M, APL Mantel Test). 
For the M1-AML samples, cells were set up in triplicate and incubated with compounds for 5 days (10 µM ATRA, 5 µM R-(-)-apomorphine HCl, 70 µM erythro-9-(2-hydroxy-3-nonyl) adenine 
HCl, 70 µM 16-ketoestradiol, 7.5 µM cyclazosin HCl, 1 µM 1,10-phenanthroline, and 50 µM 
pergolide methansulfonate). Untreated cells were also evaluated. Cells were stained with May-
Grunwald-Giemsa and examined with light microscopy. Cells were also evaluated with NBT 
reduction assay as described above. Cells were then evaluated at five days with lower 
concentrations of confirmed compounds: 1µM 16-ketoestradiol, and 1µM pergolide 
methanesulfonate. Negative controls were treated with 0.1% DMSO. May-Grunwald-Giemsa 
staining and the NBT reduction assay were performed as above (Supplementary Data Excel 
File, Sheet N, NBT Reduction Assay).  
H. Estrogen Derivative Testing 
HL-60 cells were treated with estrogen derivates at 10 uM for 6 days: 17 α-estradiol, β-estradiol, 
and 17-α-ethynylestradiol. NBT reduction was performed at 3 and 6 days as described above in 
triplicate and May Grunwald Giemsa staining at 5 days after cytospin preparation. Morphological 
evidence of differentiation consistent with neutrophil maturation was seen as shown below in 
Supplementary Fig. 6. These compounds also induced NBT reduction as shown in 
Supplementary Data Excel File, Sheet O, Estrogen Testing. 
Supplementary Figure 6: HL-60 Treatment with Estrogen Derivatives 
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Undifferentiated HL-60 10 µM17-α-ethynylestradiol treated
10 µM 17-α-estradiol 10 µM 17-β-estradiol  35
Raw microarray data are available at either 
http://www.broad.mit.edu/cancer/pub/GE-HTS_leuk or 
http://www.ncbi.nlm.nih.gov/geo/
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